甲基胺和神经HIV通过不同的机制抑制中部前额叶皮质中的星细胞通道功能
Lihua Chen1, Stefanie L Cassoday1, Joao I Mamede1
1Department of Microbial Pathogens and Immunity, RUSH University Medical Center, Chicago, IL, United States.
Frontiers in pharmacology
|December 10, 2025
概括
甲基胺和神经HIV通过抑制K+通道损害了星细胞功能. 联合使用加剧了天体细胞功能障碍,可能会在MUD和神经HIV中恶化神经元问题.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 甲基胺使用障碍 (MUD) 破坏中部前额叶皮层 (mPFC) 神经功能.
- 与艾滋病毒相关的神经认知障碍 (neuroHIV) 通常与MUD同时发生,进一步复杂化神经健康.
- 无论是MUD还是neuroHIV,都会对神经细胞支持神经元功能的关键细胞天体细胞产生负面影响,但机制尚不清楚.
研究的目的:
- 研究MUD和神经HIV对天体细胞功能的影响,特别关注K+通道活动.
- 在结合MUD和神经HIV的背景下阐明天体细胞功能障碍的潜在机制.
主要方法:
- 利用HIV-1转基因大鼠作为神经HIV的模型,并多次给他们注射甲基胺.
- 评估了mPFC星体细胞的电生理特性,重点关注急性和重复性甲基胺暴露后的K+通道活性.
- 研究了微氨基关联受体1 (TAAR1) 信号传导在调解观察到的效果中的作用.
主要成果:
- 甲基胺和神经HIV都抑制了天体细胞K+通道活性.
- 结合甲基胺和神经HIV暴露导致了最显著的天体细胞功能障碍.
- 阻断TAAR1信号消除了甲基胺诱导的K+通道抑制,但不是神经HIV诱导的抑制.
结论:
- 甲基胺和神经HIV独立和协同抑制星球细胞功能.
- 这种天体细胞功能障碍可能导致在MUD和neuroHIV中观察到的神经元功能障碍.
- TAAR1和化学因子受体信号通路与甲基胺和神经HIV对天体细胞K+通道的影响有关.
相关概念视频
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
741
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
741
01:26Neurochemical Transmission: Sites of Drug Action
3.4K
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
3.4K
01:29Drugs Affecting Neurotransmitter Synthesis
2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K
01:25Adrenergic Agonists: Indirect-Acting Agents
2.5K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.5K
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.5K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.5K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
790
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
790